The search found 3764 results.
Video
This video highlights the benefits of electronic prescribing of controlled substances (EPCS) and provides an overview of the DEA regulatory requirements for EPCS.
Blog
Electronic prescribing of controlled substances (EPCS) has many benefits for prescribers, patients, IT, and pharmacy and hospital administration. But the DEA requirements for EPCS introduce complexities that need to be considered when developing a project plan.
Video
Methodist Health System (Omaha, Neb.) leverages fingerprint biometric authentication from Imprivata to enable e-Prescribing of controlled substances to improve patient satisfaction, eliminate dual-prescribing workflows and address drug diversion.
Blog
Learn how to successfully implement a new clinical communications solution: Listen to your clinical crew and empower them to rally together effectively
Blog
Ensure EPCS success by following these six comprehensive steps. Deploying Electronic Prescribing of Controlled Substances shouldn't be a headache.
Press
Lexington, Mass. — December 18, 2014— Imprivata® (NYSE: IMPR) today announced that members of management will participate in the 33rd Annual J.P. Morgan Healthcare Conference.
Omar Hussain, President and CEO, and Jeff Kalowski, Chief Financial Officer, will present at the conference in San Francisco, California on Wednesday, January 14th at 3:30 PM PST.
An audio webcast of the presentation will be available live and archived on Imprivata’s investor relations website at http://investor.imprivata.com